FREE Biopharma Daily Stock Updates - 02/16/21

Want to access our searchable database of catalysts and companies? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!

$MRNA -3% Provides US vaccine supply update. MRNA has supplied 45.4 million doses of Moderna COVID-19 Vaccine to U.S. Government to date. source

$CRTX -35% FDA puts clinical hold on ongoing phase 2/3 study due to hepatic AE's. Ph 3 remains on track to report data in Q4 2021. source

$KALA +10% Express Scripts, one of the leading pharmacy benefit managers (PBM) in the United States, has added EYSUVIS to its National Preferred, Basic and High Performance Formularies. source

$BLUE -38% Phase 1/2 and Phase 3 trials of LentiGlobin for sickle cell disease suspended by company after serious AE's reported of acute myeloid leukemia (AML). source

$SESN +8% BLA accepted and PDUFA target date set for 8/18/21 with priority review. FDA noted they do not anticipate holding an ADCOM meeting. source

$GMDA -5% Offering

$YMAB -6% Offering

$VSTM +17% Baker Brothers holding. source